Kenro Hirata

Scopus著者プロファイル

ウェブサイトhttps://k-ris.keio.ac.jp/html/100003002_ja.html

年別の研究成果

Pureに変更を加えた場合、すぐここに表示されます。

フィンガープリント

Kenro Hirataが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。

1 類似のプロファイル

991 被引用数
17 h-index
39 Article
2 Comment/debate
2 Review article

Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data
Shimozaki, K., Sukawa, Y., Sato, Y., Horie, S., Chida, A., Tsugaru, K., Togasaki, K., Kawasaki, K., Hirata, K., Hayashi, H., Hamamoto, Y. & Kanai, T., 2021 7, In: Future Oncology. 17, 20, p. 2593-2603 11 p.
研究成果: Article › 査読

Open Access
An investigator-initiated phase 2 study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability—high advanced gastric or esophagogastric junction cancer (No limit, wjog13320g/ca209-7w7)
Kawakami, H., Hironaka, S., Esaki, T., Chayama, K., Tsuda, M., Sugimoto, N., Kadowaki, S., Makiyama, A., Machida, N., Hirano, H., Hirata, K., Hara, H., Yabusaki, H., Komatsu, Y. & Muro, K., 2021 2 2, In: Cancers. 13, 4, p. 1-12 12 p., 805.
研究成果: Article › 査読

Open Access
Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis
Hayashi, Y., Hosoe, N., Takabayashi, K., Limpias Kamiya, K. J. L., Tsugaru, K., Shimozaki, K., Hirata, K., Fukuhara, K., Fukuhara, S., Mutaguchi, M., Sujino, T., Sukawa, Y., Hamamoto, Y., Naganuma, M., Takaishi, H., Shimoda, M., Ogata, H. & Kanai, T., 2021 6, In: Digestive Diseases and Sciences. 66, 6, p. 2129-2134 6 p.
研究成果: Article › 査読

2 被引用数 (Scopus)
The entire intestinal tract surveillance using capsule endoscopy after immune checkpoint inhibitor administration: A prospective observational study
Shimozaki, K., Hirata, K., Horie, S., Chida, A., Tsugaru, K., Hayashi, Y., Kawasaki, K., Miyanaga, R., Hayashi, H., Mizuno, R., Funakoshi, T., Hosoe, N., Hamamoto, Y. & Kanai, T., 2021 3, In: Diagnostics. 11, 3, 543.
研究成果: Article › 査読

Open Access
Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis
Kayashima, A., Shimozaki, K., Hirata, K., Mutaguchi, M., Takabayashi, K., Hayashi, Y., Hosoe, N., Ogata, H., Sujino, T. & Kanai, T., 2021 2, In: Clinical journal of gastroenterology. 14, 1, p. 152-158 7 p.
研究成果: Article › 査読

平田賢郎

フィンガープリント

ネットワーク

詳細を開く

Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data

An investigator-initiated phase 2 study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability—high advanced gastric or esophagogastric junction cancer (No limit, wjog13320g/ca209-7w7)

Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis

The entire intestinal tract surveillance using capsule endoscopy after immune checkpoint inhibitor administration: A prospective observational study

Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis

平田 賢郎

フィンガープリント

ネットワーク

研究成果

Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data

An investigator-initiated phase 2 study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability—high advanced gastric or esophagogastric junction cancer (No limit, wjog13320g/ca209-7w7)

Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis

The entire intestinal tract surveillance using capsule endoscopy after immune checkpoint inhibitor administration: A prospective observational study

Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis

平田賢郎